The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer von Friboulet, Luc, Li, Nanxin, Katayama, Ryohei, Lee, Christian C, Gainor, Justin F, Crystal, Adam S, Michellys, Pierre-Yves, Awad, Mark M, Yanagitani, Noriko, Kim, Sungjoon, Pferdekamper, AnneMarie C, Li, Jie, Kasibhatla, Shailaja, Sun, Frank, Sun, Xiuying, Hua, Su, McNamara, Peter, Mahmood, Sidra, Lockerman, Elizabeth L, Fujita, Naoya, Nishio, Makoto, Harris, Jennifer L, Shaw, Alice T, Engelman, Jeffrey A

Volltext

Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5‑Chloro‑N2‑(2-isopropoxy-5-methyl-4-... von Marsilje, Thomas H, Pei, Wei, Chen, Bei, Lu, Wenshuo, Uno, Tetsuo, Jin, Yunho, Jiang, Tao, Kim, Sungjoon, Li, Nanxin, Warmuth, Markus, Sarkisova, Yelena, Sun, Frank, Steffy, Auzon, Pferdekamper, AnneMarie C, Li, Allen G, Joseph, Sean B, Kim, Young, Liu, Bo, Tuntland, Tove, Cui, Xiaoming, Gray, Nathanael S, Steensma, Ruo, Wan, Yongqin, Jiang, Jiqing, Chopiuk, Greg, Li, Jie, Gordon, W. Perry, Richmond, Wendy, Johnson, Kevin, Chang, Jonathan, Groessl, Todd, He, You-Qun, Phimister, Andrew, Aycinena, Alex, Lee, Christian C, Bursulaya, Badry, Karanewsky, Donald S, Seidel, H. Martin, Harris, Jennifer L, Michellys, Pierre-Yves

Volltext

Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist von Pan, Shifeng, Wu, Xu, Jiang, Jiqing, Gao, Wenqi, Wan, Yongqin, Cheng, Dai, Han, Dong, Liu, Jun, Englund, Nathan P, Wang, Yan, Peukert, Stefan, Miller-Moslin, Karen, Yuan, Jing, Guo, Ribo, Matsumoto, Melissa, Vattay, Anthony, Jiang, Yun, Tsao, Jeffrey, Sun, Fangxian, Pferdekamper, AnneMarie C, Dodd, Stephanie, Tuntland, Tove, Maniara, Wieslawa, Kelleher, Joseph F, Yao, Yung-mae, Warmuth, Markus, Williams, Juliet, Dorsch, Marion

Volltext

Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro- N 2-(2-isopropoxy-5-methyl-... von Marsilje, Thomas H., Pei, Wei, Chen, Bei, Lu, Wenshuo, Uno, Tetsuo, Jin, Yunho, Jiang, Tao, Kim, Sungjoon, Li, Nanxin, Warmuth, Markus, Sarkisova, Yelena, Sun, Frank, Steffy, Auzon, Pferdekamper, AnneMarie C., Li, Allen G., Joseph, Sean B., Kim, Young, Liu, Bo, Tuntland, Tove, Cui, Xiaoming, Gray, Nathanael S., Steensma, Ruo, Wan, Yongqin, Jiang, Jiqing, Chopiuk, Greg, Li, Jie, Gordon, W. Perry, Richmond, Wendy, Johnson, Kevin, Chang, Jonathan, Groessl, Todd, He, You-Qun, Phimister, Andrew, Aycinena, Alex, Lee, Christian C., Bursulaya, Badry, Karanewsky, Donald S., Seidel, H. Martin, Harris, Jennifer L., Michellys, Pierre-Yves

Volltext

EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor von Jia, Yong, Juarez, Jose, Li, Jie, Manuia, Mari, Niederst, Matthew J, Tompkins, Celin, Timple, Noelito, Vaillancourt, Mei-Ting, Pferdekamper, AnneMarie Culazzo, Lockerman, Elizabeth L, Li, Chun, Anderson, Jennifer, Costa, Carlotta, Liao, Debbie, Murphy, Eric, DiDonato, Michael, Bursulaya, Badry, Lelais, Gerald, Barretina, Jordi, McNeill, Matthew, Epple, Robert, Marsilje, Thomas H, Pathan, Nuzhat, Engelman, Jeffrey A, Michellys, Pierre-Yves, McNamara, Peter, Harris, Jennifer, Bender, Steven, Kasibhatla, Shailaja

Volltext

Abstract 957: The ALK inhibitor LDK378 overcomes crizotinib resistance in non-small cell lung cancer von Friboulet, Luc, Li, Nanxin, Katayama, Ryohei, Lee, Christian C., Gainor, Justin F., Crystal, Adam S., Michellys, Pierre-Yves, Awad, Mark M., Yanagitani, Noriko, Kim, Sungjoon, Pferdekamper, AnneMarie, Li, Jie, Kasibhatla, Shailaja, Sun, Frank, Sun, Xiuying, Hua, Su, McNamara, Peter, Mahmood, Sidra, Lockerman, Elizabeth L., Fujita, Naoya, Nishio, Makoto, Harris, Jennifer L., Shaw, Alice T., Engelman, Jeffrey A.

Volltext